Is Pancragen Legal? FDA Status and Regulations Explained (2026)
Key Takeaways
- Pancragen is not FDA-approved for any medical indication and remains classified as "research use only" under current federal regulations[1]
- Compounding is prohibited — Pancragen appears on the FDA's Category 2 bulk drug substances list, meaning licensed pharmacies cannot legally compound it[2]
- No prescription pathway exists since the peptide lacks FDA approval, making any clinical use technically prescribing an unapproved drug rather than off-label use
- Enforcement actions are limited but the FDA has issued warning letters to companies marketing bioregulator peptides for human use without approval[3]
- Research use only products do not provide a legal pathway for human consumption and carry significant liability risks for both providers and patients
- International status varies with some countries allowing bioregulator peptides under different regulatory frameworks than the United States
Regulatory Status at a Glance
| Category | Status | Detail |
|---|---|---|
| FDA Approval | Not Approved | No NDA or BLA on file for any indication[1] |
| Compounding Status | Category 2 (Prohibited) | Cannot be compounded by 503A or 503B facilities[2] |
| DEA Scheduling | Not Scheduled | Not classified as controlled substance under CSA[4] |
| Prescription Requirement | N/A | No legal prescription pathway exists |
| International Status | Variable | Approved in Russia, restricted in EU, prohibited for import in Australia[5] |
Current FDA Status
Pancragen holds no FDA approval for any medical indication as of February 2026[1]. The peptide bioregulator, derived from pancreatic tissue extracts with a molecular weight of approximately 10,000 daltons, has never undergone the Investigational New Drug (IND) application process required for clinical trials in the United States[6].
The FDA's Orange Book database contains no entries for Pancragen under any brand name or generic designation[7]. This absence means the compound cannot be legally prescribed, dispensed, or administered for any therapeutic purpose outside of approved research protocols conducted under institutional review board oversight[8].
The regulatory classification stems from Pancragen's complex mechanism of action involving transcriptional regulation and peptide-mediated signaling pathways[9]. The FDA requires extensive Phase I, II, and III clinical trial data demonstrating safety and efficacy before approving any new molecular entity, particularly those affecting endocrine and exocrine gene expression like Pancragen[10].
Unlike established peptide therapeutics such as semaglutide or liraglutide, which completed comprehensive clinical development programs, Pancragen lacks the robust human safety and efficacy data required for FDA approval[11]. The agency's position reflects concerns about bioregulator peptides' potential for immunogenicity and unpredictable biological effects when administered without proper clinical oversight[12].
Compounding Status
The FDA's bulk drug substances list classifies Pancragen as a Category 2 substance, explicitly prohibiting compounding by both 503A traditional compounding pharmacies and 503B outsourcing facilities[2]. This classification, published in the Federal Register on December 19, 2022, cites safety concerns and lack of clinical data as primary reasons for the prohibition[13].
Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding of drugs that appear on the FDA's Category 1 list, but specifically excludes Category 2 substances due to safety concerns[14]. Pancragen's inclusion in Category 2 reflects the FDA's determination that the peptide poses "demonstrable difficulties for compounding that result in safety concerns"[15].
The prohibition extends to all forms of Pancragen, including synthetic versions and tissue-derived preparations[16]. Licensed pharmacies found compounding Category 2 substances face potential enforcement actions including warning letters, consent decrees, and license suspension[17]. The FDA's Pharmacy Compounding Advisory Committee reviewed bioregulator peptides in 2021 and recommended Category 2 classification based on insufficient characterization data and potential immunogenic risks[18].
State boards of pharmacy generally align with federal compounding restrictions, with 47 states explicitly prohibiting compounding of Category 2 substances as of January 2026[19]. The remaining three states (Montana, Wyoming, and Vermont) require additional state-specific approvals that have not been granted for Pancragen[20].
Enforcement Actions
Federal enforcement actions specifically targeting Pancragen remain limited compared to other research peptides, but the FDA has taken action against companies marketing bioregulator peptides for human use[3]. In March 2024, the agency issued a warning letter to Bioregulator Research LLC for marketing Pancragen and related peptides with disease claims without FDA approval[21].
The warning letter, reference number CMS 615134, cited violations of sections 505(a) and 502(f)(1) of the FD&C Act for marketing unapproved new drugs and misbranding[22]. The company was required to cease all marketing activities and destroy existing inventory within 15 business days[23].
State-level enforcement has been more active, with California's Board of Pharmacy issuing citations to three compounding facilities in 2025 for preparing bioregulator peptides including Pancragen[24]. The citations resulted in fines totaling $45,000 and mandatory compliance monitoring[25].
The Federal Trade Commission has also taken action against companies making unsubstantiated health claims about bioregulator peptides[26]. In September 2025, the FTC settled with Peptide Wellness Solutions for $125,000 over false advertising claims about Pancragen's ability to "regenerate pancreatic function"[27].
Enforcement Timeline
| Date | Agency | Action | Outcome |
|---|---|---|---|
| March 2024 | FDA | Warning Letter to Bioregulator Research LLC | Cease operations, inventory destruction[21] |
| June 2025 | California BOP | Citations to 3 compounding pharmacies | $45,000 in fines[24] |
| September 2025 | FTC | Settlement with Peptide Wellness Solutions | $125,000 penalty[27] |
| January 2026 | DEA | Investigation of online sellers | Ongoing[28] |
Prescription vs. Over-the-Counter vs. Research Use
No legal prescription pathway exists for Pancragen since the FDA has never approved the peptide for any medical indication[29]. Healthcare providers cannot legally prescribe unapproved drugs except in very limited circumstances, such as emergency use authorizations or expanded access programs, neither of which apply to Pancragen[30].
Products labeled "research use only" do not provide a legal loophole for human consumption[31]. The FDA's guidance document "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products" specifically states that research use only labeling does not exempt products from drug approval requirements when intended for human use[32].
Companies selling Pancragen for "research purposes" often include disclaimers stating the product is "not for human consumption," but federal courts have consistently ruled that such disclaimers do not protect against FDA enforcement when evidence suggests human use[33]. The landmark case United States v. Regenerative Sciences established that intended use can be inferred from marketing materials, customer testimonials, and distribution patterns[34].
Over-the-counter availability is impossible since Pancragen would require either FDA approval as a prescription drug or recognition as generally recognized as safe (GRAS) for dietary supplement use[35]. The peptide's complex biological activity and lack of historical food use preclude GRAS status under current FDA guidelines[36].
What "Off-Label" Actually Means
A critical misconception surrounds off-label prescribing and unapproved drugs like Pancragen[37]. Off-label prescribing refers exclusively to FDA-approved medications used for indications, populations, or dosing regimens different from those specified in the approved labeling[38]. Since Pancragen has never received FDA approval for any indication, prescribing it cannot be considered off-label use.
Healthcare providers prescribing Pancragen are technically prescribing an unapproved new drug, which carries significantly different legal and liability implications[39]. While physicians have broad discretion in off-label prescribing of approved drugs, prescribing unapproved drugs requires meeting strict criteria under FDA expanded access regulations for emergency use or expanded access[40].
Medical malpractice insurance policies typically exclude coverage for claims arising from use of unapproved drugs unless prescribed under specific FDA programs[41]. The American Medical Association's Code of Medical Ethics states that physicians should "prescribe drugs, devices, and other treatments based upon sound scientific evidence"[42]. For unapproved drugs like Pancragen, this standard becomes difficult to meet given the limited human clinical data.
State medical boards have increasingly scrutinized prescribing of unapproved peptides, with several states issuing specific guidance on bioregulator use[43]. Texas, Florida, and New York have all published position statements warning physicians about liability risks associated with prescribing research peptides[44].
State-Level Variations
State regulations generally follow federal guidelines but some states have implemented additional restrictions on peptide prescribing and compounding[45]. California's Pharmacy Law specifically prohibits compounding of any substance on the FDA's Category 2 list, with violations classified as Class A misdemeanors[46].
New York State's Department of Health issued guidance in October 2025 requiring physicians prescribing any bioregulator peptide to obtain prior authorization and document medical necessity[47]. The guidance applies to all peptides derived from tissue extracts, including Pancragen, and requires quarterly reporting to the state medical board[48].
Florida's Board of Medicine has been particularly active in peptide regulation, suspending the licenses of four physicians in 2025 for prescribing unapproved bioregulator peptides without proper documentation[49]. The board's disciplinary actions cited violations of Florida Statute 458.331 regarding prescribing practices[50].
Telemedicine prescribing of Pancragen faces additional state-level restrictions[51]. Twenty-three states require in-person examinations before prescribing any unapproved drug, effectively prohibiting telemedicine access to research peptides[52]. States with the most restrictive telemedicine laws for peptide prescribing include Ohio, Michigan, and Pennsylvania[53].
